The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today announced that David Brennan of AstraZeneca will be its new president, replacing Haruo Naito of pharmaceutical companiy Eisai. They also announced that California-based biotechnology company Amgen has become a member.
The group also has published its 2010 Status Report on the Pharmaceutical Industry R&D for Diseases of the Developing World, which a press release said highlights “increasing efforts of IFPMA member companies, working with partners or alone, to develop medicines and vaccines for the 10 diseases of the developing world prioritised” by the World Health Organization Special Programme for Research and Training in Tropical Diseases.
IFPMA’s 25th annual assembly was held today in Washington, DC. Event speaker Tony Taubman, head of the World Trade Organization IP Division, praised the industry event, according to a release. The theme of the assembly was a “shared commitment to global health.”